Head to Head Analysis: Spectral Diagnostics (OTCMKTS:EDTXF) vs. Positron (OTCMKTS:POSC)

Earnings & Valuation

This table compares Positron and Spectral Diagnostics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Positron	$460,000.00	119.26	-$10.60 million	($0.33)	-5.06
Spectral Diagnostics	$1.75 million	166.92	-$34.13 million	($0.10)	-9.95

Positron has higher earnings, but lower revenue than Spectral Diagnostics. Spectral Diagnostics is trading at a lower price-to-earnings ratio than Positron, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Positron and Spectral Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Positron	-1,996.75%	-996.81%	-272.52%
Spectral Diagnostics	-1,378.12%	N/A	-627.93%

Volatility and Risk

Positron has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500. Comparatively, Spectral Diagnostics has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500.

Summary

Spectral Diagnostics beats Positron on 5 of the 9 factors compared between the two stocks.

About Positron

Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.

About Spectral Diagnostics

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.